Globus Medical (GMED) vs Haemonetics (HAE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Haemonetics (HAE) has outperformed Globus Medical (GMED) over the past year, gaining 134.3% versus a gain of 21.4%. Over five years, HAE leads with a +70.9% price change compared with -4.1% for GMED. Globus Medical is the larger company by market cap ($9.85 billion vs $5.44 billion), about 1.8 times the size.
On valuation, Globus Medical trades at a lower forward P/E (13.6x vs 20.5x for Haemonetics). Globus Medical converts more of its revenue into profit, with a net margin of 18.3% versus 7.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMED | HAE |
|---|---|---|
| Share price | $73.33 | $119.47 |
| Market cap | $9.85B | $5.44B |
| 1-day change | -0.57% | +17.46% |
| YTD return | -16.01% | +49.06% |
| 1-year return | +21.37% | +134.35% |
| 5-year return | -4.06% | +70.89% |
| P/E ratio (TTM) | 18.80 | 57.71 |
| Forward P/E | 13.58 | 20.53 |
| EPS (TTM) | $3.90 | $2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.94B | $1.33B |
| Revenue growth (YoY) | +16.65% | -1.97% |
| Net income (latest FY) | $537.87M | $97.31M |
| Gross margin | 67.41% | 59.04% |
| Operating margin | 16.33% | 11.75% |
| Net margin | 18.30% | 7.29% |
| 52-week high | $101.40 | $121.00 |
| 52-week low | $56.50 | $48.17 |
| Distance from 52-week high | -27.68% | -1.26% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +37.62% | -6.67% |
| Average volume | 1.51M | 715.68K |
| Shares outstanding | 111.83M | 45.50M |
| Employees | 6,000 | 3,009 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed GMED by 113.0 percentage points over the past year.
- Haemonetics trades at a higher earnings multiple (57.7x vs 18.8x trailing P/E).
- Globus Medical is more profitable, keeping 18.3 cents of every revenue dollar as net income versus 7.3 cents for Haemonetics.
- Globus Medical grew revenue faster in its latest fiscal year (+16.65% vs -1.97%).
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
GMED vs HAE FAQ
Which is bigger, Globus Medical or Haemonetics?
Globus Medical (GMED) is larger, with a market capitalization of $9.85B compared with $5.44B for Haemonetics (HAE).
Which stock has performed better over the past year, GMED or HAE?
HAE returned +134.35% over the past 12 months, compared with +21.37% for GMED (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMED or HAE?
GMED has the lower trailing P/E at 18.8, versus 57.7 for HAE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Globus Medical and Haemonetics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.